• Pharmaceutical giants Novo Nordisk and Eli Lilly are aggressively lobbying the Trump administration on weight-loss drug policies, spending millions in Q1 2025 alone.
  • Key issues include Medicare coverage restrictions and regulation of generic alternatives, with the administration expressing cost concerns.
  • The weight-loss drug market, after years of shortages, is stabilizing, shifting the competitive dynamics between brand-name and generic manufacturers.

Pharmaceutical Lobbying Intensifies

President Donald Trump has engaged in discussions with major pharmaceutical companies about weight-loss medications amid a heated lobbying campaign in Washington. The administration appears hesitant to support expanded Medicare coverage or relax regulations on compounded alternatives, citing budgetary pressures.

Novo Nordisk and Eli Lilly have deployed significant resources, with each company spending over $3 million on lobbying efforts this quarter. They've retained prominent firms like Avoq and Holland & Knight to push their agenda, according to people familiar with the matter.

Policy Battles Take Shape

At stake are two critical issues: whether to maintain the decades-old ban on Medicare covering weight-loss drugs, and how strictly to regulate compounded versions of medications like Ozempic and Wegovy. While proponents argue expanded access would reduce long-term healthcare costs from obesity-related conditions, administration officials remain wary of the upfront price tag.

"The cost calculations are daunting," said one White House aide who requested anonymity to discuss private deliberations. "But the pressure from industry and patient advocates is relentless."

Market Implications

The weight-loss drug sector, valued at billions annually, faces potential upheaval depending on the administration's decisions. After supply shortages in 2022-2024 drove patients toward generics, brand-name manufacturers now seek to reclaim market share through regulatory channels. Analysts suggest the outcome could significantly impact stock valuations for both pharmaceutical giants and generic manufacturers.

Representatives for Novo Nordisk and Eli Lilly declined to comment on specific discussions with the administration, though company statements emphasize their commitment to "expanding patient access to innovative treatments." The White House didn't respond to requests for comment by publication time.